Chapter 1.  Cancer Biomarkers For Gastrointestinal Stromal Tumor (GIST) Market  – Scope & Methodology
1.1    Market Segmentation
1.2    Scope, Assumptions & Limitations
1.3    Research Methodology
1.4    Primary Sources
1.5    Secondary Sources 
Chapter 2.  Cancer Biomarkers For Gastrointestinal Stromal Tumor (GIST) Market – Executive Summary
2.1    Market Size & Forecast – (2023 – 2030) ($M/$Bn)
2.2    Key Trends & Insights
           2.2.1    Demand Side
           2.2.2    Supply Side
2.3    Attractive Investment Propositions
2.4    COVID-19 Impact Analysis 
Chapter 3.  Cancer Biomarkers For Gastrointestinal Stromal Tumor (GIST) Market – Competition Scenario
3.1    Market Share Analysis & Company Benchmarking
3.2    Competitive Strategy & Development Scenario
3.3    Competitive Pricing Analysis
3.4    Supplier-Distributor Analysis
Chapter 4.  Cancer Biomarkers For Gastrointestinal Stromal Tumor (GIST) Market - Entry Scenario
4.1    Regulatory Scenario
4.2    Case Studies – Key Start-ups
4.3    Customer Analysis
4.4    PESTLE Analysis
4.5    Porters Five Force Model
           4.5.1    Bargaining Power of Suppliers
           4.5.2    Bargaining Powers of Customers
           4.5.3    Threat of New Entrants
           4.5.4    Rivalry among Existing Players
           4.5.5    Threat of Substitutes 
Chapter 5.  Cancer Biomarkers For Gastrointestinal Stromal Tumor (GIST) Market – Landscape
5.1    Value Chain Analysis – Key Stakeholders Impact Analysis
5.2    Market Drivers
5.3    Market Restraints/Challenges
5.4    Market Opportunities
Chapter 6.  Cancer Biomarkers For Gastrointestinal Stromal Tumor (GIST) Market –  By Therapy
6.1    Introduction/Key Findings   
6.2    Targeted therapy
6.3    Chemotherapy
6.4    Radiation therapy
6.5    Y-O-Y Growth trend Analysis   By Therapy
6.6    Absolute $ Opportunity Analysis by   By Therapy, 2023-2030
 Chapter 7.  Cancer Biomarkers For Gastrointestinal Stromal Tumor (GIST) Market –    By End User
7.1    Introduction/Key Findings   
7.2    Hospitals
7.3    Clinics
7.4    Specialized Cancer Treatment Centres
7.5    Y-O-Y Growth  trend Analysis     By End User
7.6    Absolute $ Opportunity Analysis    By End User, 2023-2030  
Chapter 8.  Cancer Biomarkers For Gastrointestinal Stromal Tumor (GIST) Market , By Geography – Market Size, Forecast, Trends & Insights
8.1    North America
           8.1.1    By Country
                      8.1.1.1    U.S.A.
                      8.1.1.2    Canada
                      8.1.1.3    Mexico
                      8.1.1.4    By Therapy
           8.1.2      By End User
           8.1.3    Countries & Segments - Market Attractiveness Analysis
8.2    Europe
           8.2.1    By Country
                      8.2.1.1    U.K
                      8.2.1.2    Germany
                      8.2.1.3    France
                      8.2.1.4    Italy
                      8.2.1.5    Spain
                      8.2.1.6    Rest of Europe
           8.2.2      By Therapy 
           8.2.3       By End User
           8.2.4    Countries & Segments - Market Attractiveness Analysis
8.3    Asia Pacific
           8.3.1    By Country
                      8.3.1.1    China
                      8.3.1.2    Japan
                      8.3.1.3    South Korea
                      8.3.1.4    India      
                      8.3.1.5    Australia & New Zealand
                      8.3.1.6    Rest of Asia-Pacific
           8.3.2      By Therapy
           8.3.3       By End User
           8.3.4    Countries & Segments - Market Attractiveness Analysis
8.4    South America
           8.4.1    By Country
                      8.4.1.1    Brazil
                      8.4.1.2    Argentina
                      8.4.1.3    Colombia
                      8.4.1.4    Chile
                      8.4.1.5    Rest of South America
           8.4.2      By Therapy
           8.4.3       By End User
           8.4.4    Countries & Segments - Market Attractiveness Analysis
8.5    Middle East & Africa
           8.5.1    By Country
                      8.5.1.1    United Arab Emirates (UAE)
                      8.5.1.2    Saudi Arabia
                      8.5.1.3    Qatar
                      8.5.1.4    Israel
                      8.5.1.5    South Africa
                      8.5.1.6    Nigeria
                      8.5.1.7    Kenya
                      8.5.1.8    Egypt
                      8.5.1.9    Rest of MEA
8.5.2      By Therapy
8.5.3       By End User
8.5.4    Countries & Segments - Market Attractiveness Analysis 
Chapter 9.  Cancer Biomarkers For Gastrointestinal Stromal Tumor (GIST) Market – Company Profiles – (Overview,    Cancer Biomarkers For Gastrointestinal Stromal Tumor (GIST) Market  Portfolio, Financials, Strategies & Developments)
9.1    Arog Pharmaceuticals
9.2    Taiho Pharmaceutical
9.3    Turning Point Therapeutics, Inc.
9.4    Cogent Biosciences, Inc.
9.5    Plexxikon Inc.
9.6    Theseus Pharmaceuticals
9.7    Exelixis, Inc.
9.8    Ipsen
9.9    Bristol-Myers Squibb
9.10    Takeda